High baseline C-reactive protein levels predict partial type 2 diabetes mellitus remission after biliopancreatic diversion

Nutr Metab Cardiovasc Dis. 2017 May;27(5):423-429. doi: 10.1016/j.numecd.2017.01.007. Epub 2017 Feb 3.

Abstract

Background and aims: Several studies demonstrated that surgery can improve inflammation parameters, such as C-reactive protein (CRP). Few biomarkers have been investigated to potentially predict type 2 diabetes mellitus (T2DM) remission. We aimed at determining whether pre-surgery serum CRP levels could predict T2DM remission after 3 years in patients undergoing bariatric surgery, especially biliopancreatic diversion (BPD).

Methods and results: This study was conducted from 2007 to 2009 at the Surgical Department of the University of Genoa, Italy. Forty-four patients with T2DM undergoing BPD (n = 38) or Roux-en-Y gastric bypass (n = 6) were enrolled. The primary endpoint was to evaluate whether pre-surgery CRP levels could predict T2DM partial remission at 3-year follow-up. Secondary endpoints were to assess whether glycaemic, lipid, and inflammatory parameters modified during the follow-up. At baseline, patients with T2DM ranged from overweight to morbid obesity, had mild dyslipidaemia, and a low-grade inflammation. Bariatric surgery improved body weight, lipid and glycaemic profile both at 1- and 3-year follow-up. Pre-surgery CRP levels progressively decreased at 1- and 3-year follow-up. Among inflammatory pre-surgery parameters, only high CRP levels were shown to predict T2DM partial remission after 3 years. Multivariate analysis confirmed the predictive value of pre-surgery CRP levels independently of age, gender, type of surgery, and body mass index.

Conclusion: Bariatric surgery, in particular BPD, improved both metabolic and inflammatory biomarkers at 1- and 3-year follow-up. Pre-surgery high CRP levels predicted 3-year T2DM partial remission, indicating a promising target population to be especially treated with BPD.

Keywords: Bariatric surgery; C-reactive protein; Glycaemic control; Inflammation; Type 2 diabetes.

MeSH terms

  • Biliopancreatic Diversion*
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • C-Reactive Protein / analysis*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / etiology
  • Female
  • Humans
  • Inflammation Mediators / blood*
  • Italy
  • Lipids / blood
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / complications
  • Obesity / diagnosis
  • Obesity / surgery*
  • Predictive Value of Tests
  • Prospective Studies
  • Remission Induction
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Up-Regulation
  • Weight Loss

Substances

  • Biomarkers
  • Blood Glucose
  • Inflammation Mediators
  • Lipids
  • C-Reactive Protein